CureChat
AI-driven Solutions for Chronic Disease Management
Company Overview
Snapshot
Founded in April 2023 by Shimon Zilbershlag, CureChat operates with 1–10 employees. The company is in the Pre-Funding stage, focusing on AI-driven solutions for chronic disease management. In August 2024, CureChat's innovative Dana chatbot for diabetes management was highlighted, showcasing its potential in digital health.
Business overview
CureChat is a digital health company specializing in AI-driven solutions for chronic disease management. Its core product, Dana, is an AI-powered diabetes assistant that offers free, personalized, and medically accurate support based on ADA guidelines. The company focuses on improving diabetes education and accessibility, particularly in emerging markets, while ensuring privacy and compliance with healthcare standards, operating within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Patient Engagement.
Strategic signal
In August 2024, CureChat's Dana chatbot was featured, emphasizing its role in reimagining diabetes management through AI. This highlights the company's commitment to leveraging artificial intelligence to provide accessible and personalized healthcare solutions, signaling its potential to disrupt traditional chronic disease management approaches and attract further investment in the digital health space.
Log in to access full profile ›Company Intelligence Q&A
- When was CureChat founded?
- CureChat was founded in April 2023.
- Who is the founder of CureChat?
- Shimon Zilbershlag is the founder and CEO of CureChat.
- What is CureChat's primary product?
- CureChat's primary product is Dana, an AI-powered diabetes assistant that provides personalized and medically accurate support.
- What is the focus of CureChat's technology?
- CureChat focuses on AI-driven solutions for chronic disease management, particularly improving diabetes education and accessibility in emerging markets.
- What significant recognition did CureChat receive in 2024?
- In August 2024, CureChat's innovative Dana chatbot for diabetes management was highlighted in a feature, discussing its potential to transform chronic disease care.